SBIR/STTR Research Award
Development of Praedicare Dx as CDx for AML Period of Performance: September 19, 2014 through September 18, 2015
Award amount
$1,499,743Program and phase
SBIR · Phase IIAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Eutropics Pharmaceuticals, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- VYD9LKBYHHQ3
- Solicitation number
- Not reported
- Topic code
- DCCPS
Research abstract
Not Available
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Commercializing Praedicare Dx TM platform for guiding cancer treatments
- IGF::OT::IGF OTHER FUNCTIONS TOPIC 277, DEVELOPING BH3 PROFILING AS A COMPANION DIAGNOSTIC FOR VELCADE TREATMENT FOR MULTIPLE MYELOMA
- IGF::OT::IGF OTHER FUNCTIONS RandD- BIOMEDICAL (BASIC RESEARCH)
- BH3 Profiling as a Companion Diagnostic For Velcade
- Development of small molecule inhibitor of Mcl-1 for cancer treatment
Research funding history
7 SBIR/STTR records share this UEI (2008–2017). Reported award amounts total $8,073,930. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services